[日本語] The Global Antibiotic Research and Development Partnership (GARDP), the Clinton Health Access Initiative (CHAI) and Shionogi & Co., Ltd today announced a Memorandum of … GARDP, CHAI and Shionogi announce MOU to increase access to antibiotic to treat antimicrobial resistant infections in low- and middle-income countries
GARDP and InfectoPharm are partnering to develop improved treatment options, using combinations of existing antibiotics, for neonatal sepsis, a leading cause of death and disability in newborns up to 28 days old. Since children of this age do not have a functioning immune system, they are more prone to developing infections and less able to overcome them.
GARDP has been granted additional funding by the Government of Japan to support the fight against drug-resistant infections, contributing to research and development into new treatments against the bacterial infections that pose the greatest threat to global health.
GARDP and the Global Antimicrobial Resistance Innovation Fund, part of the UK Department of Health and Social Care, are pleased to announce £1 million of funding to support GARDP’s efforts to develop treatments for the drug-resistant infections that pose the greatest threat to global health.
GARDP is very pleased to announce renewed funding by the South African Medical Research Council (SAMRC) to tackle drug-resistant infections. The SAMRC is providing an additional 3.9 million South African rand (ZAR) to support GARDP’s activities in developing new and improved antibiotic treatments for drug-resistant infections that pose the greatest threat to health.
GARDP and the Indian Council of Medical Research have signed a Memorandum of Understanding to explore joint opportunities to tackle antibiotic resistance in India and globally.
GARDP and the French Ministry for Europe and Foreign Affairs have signed a Declaration of Intent to explore opportunities to collaborate on and strengthen activities to tackle antibiotic resistance.
GARDP and Entasis Therapeutics announced today the activation of the first site in Thailand as part of a global phase 3 clinical study of zoliflodacin for the treatment of gonorrhoea.
GARDP and the Federal Council have signed an agreement relating to the privileged status of the organization in Switzerland. By signing this agreement, the Federal Council recognizes the major role played at the international level by GARDP in the fight against antibiotic resistance.
The UK government has announced an additional £1.5 million of funding to develop a new treatment for gonorrhoea. This investment, on top of £3.5 million committed in 2019, will support GARDP in the development and availability of zoliflodacin, a novel antibiotic, which is currently being assessed as part of a global phase 3 trial for safety and effectiveness as a treatment for gonorrhoea.